Clinical trial for Alzheimer Disease
Official title First-in-Human Evaluation of an Astrocytic Glutamate Transporter (EAAT2) PET Tracer in Dementia
ClinicalTrials.gov ID: NCT05374278
What this study is testing
What is [18F]RP-115?
This is an investigational imaging agent being studied to help detect early changes in the brain for Alzheimer's disease. It is designed to bind to specific proteins in the brain that are involved in glutamate transport, allowing doctors to see areas of change on a PET scan.
Plain-language explanation of the investigational treatment. It is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- This study is testing whether the PET tracer [18F]RP-115 is safe and can help detect early brain changes in people with Alzheimer’s disease or frontotemporal dementia.
- Who it's for
- You may be able to join if you have Alzheimer’s disease or frontotemporal dementia and are willing to have a PET scan.
- What's involved
- You will have a PET scan that uses a small amount of a radioactive tracer. The scan will look at your brain for early changes linked to dementia.
- Time commitment
- The study lasts a few weeks and includes one PET scan visit and a few follow‑up check‑ins.
- Phase 2: a mid-size study of how well it works
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 40 to 75. Healthy volunteers may be eligible.
You may be able to join if
- Age 40-75
- Age-suitable BMI
- Ability to provide written informed consent and willingly comply with protocol requirements or has a legal authorized representative/guardian who...
- No apparent physical disorder.
- Radial, ulnar, or brachial artery suitable for catheterization.
You likely can't join if
- Unable to provide written informed consent and unwilling to comply with protocol requirements, or does not have a legal authorized...
- Inadequate arterial access.
- Receipt of radioisotope \ two weeks) PET scans.
- The performed [18F]RP-115 scan(s) must not represent \> 3 PET studies total within one year.
- Contra-indication to magnetic resonance, including permanent pacemaker, implantable metallic device, etc.; or severe claustrophobia.
- Participants who are pregnant (female patients of childbearing age will be tested prior to injection of tracer- positive test excludes from the study)
See the full eligibility criteria
- Age 40-75
- Age-suitable BMI
- Ability to provide written informed consent and willingly comply with protocol requirements or has a legal authorized representative/guardian who provides surrogate informed consent.
- No apparent physical disorder.
- Radial, ulnar, or brachial artery suitable for catheterization.
- Non-smoker, and not taking OTC nicotine cessation - to limit peripheral metabolism events.
- Must have a study partner (informant) who spends a minimum average of 5 hours per week with the participant (e.g.
- Recent (within 6 mo.) MME clinical scores.
- Unable to provide written informed consent and unwilling to comply with protocol requirements, or does not have a legal authorized representative/guardian who can provide surrogate informed consent.
- Inadequate arterial access.
- Receipt of radioisotope \ two weeks) PET scans.
- The performed [18F]RP-115 scan(s) must not represent \> 3 PET studies total within one year.
- Contra-indication to magnetic resonance, including permanent pacemaker, implantable metallic device, etc.; or severe claustrophobia.
- Participants who are pregnant (female patients of childbearing age will be tested prior to injection of tracer- positive test excludes from the study)
- Participants who are breast-feeding.
- Have a medical condition or other circumstances that in the opinion of the project physicians would significantly decrease chances of obtaining reliable data, achieving the study objective or completing the study.
The study team makes the final eligibility decision.
Where it is enrolling
- San Francisco, California, United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 40 years to 75 years. Healthy volunteers may be eligible. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at San Francisco, California, United States. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.